Could a single injection of AMG 691 be safe and Well-Tolerated?

NCT ID NCT07745907

Recruiting now Knowledge-focused Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time

Summary

This phase 1 trial is testing a single dose of the investigational drug AMG 691 in healthy Chinese and Japanese adults aged 18 to 60. The goal is to understand how the drug moves through the body and to check its safety and tolerability. Participants will receive one subcutaneous injection and be monitored for side effects and immune responses. The results will help guide future studies of AMG 691.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AMG 691
What this could lead to: If successful, this early study could support further development of AMG 691 as a potential treatment for various conditions, though its intended use is not yet disclosed.
What could go wrong: This is a small, early-phase trial in healthy volunteers, so results may not predict effects in patients. Safety and tolerability are still unknown, and the drug may not proceed to later stages.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma lung disorder respiratory system disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY PARTICIPANTS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

PPD - Las Vegas Research Unit
RECRUITING

Las Vegas, Nevada, 89113, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.